Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and raised the price target from $450 to $459 on ...

Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.

Vertex said its profit fell due to higher operating expenses and a $379 million intangible asset impairment charge associated with treatment for Type 1 diabetes patients, which the company said in ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company ...

Vertex Pharmaceuticals (NASDAQ:VRTX) missed on the top and bottom lines in its Q1 financial results and also raised the low ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their ...

Vertex Pharmaceuticals (NASDAQ:VRTX) will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Vertex ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $509.47, moving +1.19% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0 ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $492.47, moving +0.01% from the previous trading session. This move lagged the S&P 500's daily gain of 2.03%. Elsewhere ...

Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...